Featured
-
-
News & Views |
Manufacturer sponsorship bias in economic analyses matters
A qualitative study indicates that there is a positive selection bias towards favourable economic analysis of targeted therapies, when these are funded by the manufacturer. At a time of increasing budgetary constraints and public scrutiny of the relationship between industry and the professions, we need a more mixed economy of funding for this field.
- David Kerr
- & Ahmed Elzawawy
-
Opinion |
Personalized cancer medicine—advances and socio-economic challenges
The use of therapy that is truly targeted to the needs and biological requirements of an individual patient is an aim for many in the oncology field. Jackson and Sood discuss the implications of targeted therapies on patients and the health-care system and discuss methods that might be used to maximize efficiency, cost effectiveness and patient survival.
- David B. Jackson
- & Anil K. Sood